|Mr. Francis Gleeson B.B.A. M.B.A||Co-Founder, CEO, President & Director||267.79k||N/A||1955|
|Dr. Michael A. Rudnicki Ph.D.||Co-Founder & Chief Discovery Officer||120k||N/A||1961|
|Dr. Philip Lambert M.A., Ph.D.||Chief Scientific Officer||67.4k||N/A||1968|
|Mr. William Wasyl Jarosz||Executive Director||193.79k||N/A||1956|
|Mr. Warren Whitehead C.M.A., CPA||Head of Corporate Strategy||120k||N/A||1952|
|Ms. Elizabeth Williams CA, CPA||Chief Financial Officer||N/A||N/A||1978|
|Mr. J. Robert Hall CFA||Senior Vice President of Finance & Administration||N/A||N/A||N/A|
|Desiree Chan||Chief of Staff||N/A||N/A||N/A|
|Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA||Strategic Advisor||44.48k||N/A||1960|
|Dr. Alan Jacobs M.D.||Chief Medical Officer||N/A||N/A||N/A|
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of duchenne. The company's MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Satellos Bioscience Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.